Hong Kong has a strong legal framework to protect IP rights, which is crucial for the life science companies that invest heavily in research and development. The Hong Kong government offers a range of incentives and funding support to the life science companies, including tax concessions and grants. Hong Kong has a world-class infrastructure, including state-of-the-art research facilities, advanced healthcare system, and a highly skilled workforce.
The Pharma Partnering HK Summit 2023 is an exclusive and one of the most prestigious life sciences deal making International Conference for the Greater Bay Area coming to Hong Kong.
This platform brings together Senior Executives and Professionals from different parts of the world, focused on Business Development & Licensing, R&D Collaborations, Co-Development, Commercialisation & Distribution Deals, Fundraising, Investments, Alliances, M&A, Going Public as well as partnering Opportunities in the Broader Aspects.
The Pharma Partnering Summit brings together dealmakers of leading life science companies to put together a whole range of partnering opportunities. The Summit provides a prime Opportunity for You to meet & Network with Senior Executives of:
Business Development / Licensing / M&A / Strategic Alliances / External Innovation / Search & Evaluation / Legal & IP / Due Diligence / Scientific Assessments / Portfolie & Life cycle management / Venture Capital / Investments / Clinical Operations /Regulatory Affairs / Compliances / Commercialisation & Disturibution / Strategic R&D
And Many More from Big, Midsize and Small Pharma and Biotech Companies.
Dimitri has over 30 years’ experience in the pharmaceutical and biotech industry. He is a co-founder and former CEO of ImmuPharma plc, a drug development biotech company listed on AIM of the London Stock Exchange and previously on Euronext in Brussels. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where he was responsible for worldwide transactions with a focus on licensing of IP rights for development and commercialization. He held a similar role at Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter & Gamble in its pharmaceutical division, in senior marketing, R&D and business development positions and began his career in marketing at Novartis in 1987. Over the last 20 years, he is also the founder and Managing Director of DyoDelta Biosciences, an advisory company specializing in providing support in putting together corporate collaborations in the Life Sciences.
In the role of CEO, Joe Boncore manages MassBio’s federal affairs, state and municipal government relations, and takes the lead on initiatives to sustain Massachusetts’ economic competitiveness focusing on issues around infrastructure, workforce, and digital health. Prior to joining MassBio in September 2021, Joe served as a Massachusetts State Senator for the First Suffolk and Middlesex districts, representing his hometown of Winthrop; the Boston communities of East Boston, North End, Chinatown, Beacon Hill, Bay Village, and South End; the Cambridge neighborhoods of Cambridgeport, Riverside and MIT; and the City of Revere. While in the State Senate, Joe was the Chair of the Joint Committee on Transportation, Chair of the Senate’s Committee on Personnel and Administration, Chair of the Joint Committee on Housing, and Vice Chair of Rules. Before being elected to the state legislature in 2016, Joe practiced law specializing in criminal law in his private practice and as a public defender with Suffolk Lawyers for Justice.
Andrew Leger is a business development professional with a foundation in drug development of rare neuromuscular and metabolic diseases. He has a 15+ year track record of orchestrating high-impact results by leading cross-corporate collaborations both in science and corporate development. Both his science and business careers have allowed him to immerse in and accumulate understanding of unmet medical need experienced by patients with rare diseases. Throughout both, he has found that collaboration is a very effective way of achieving transformative advancements in medicine that make the lives of people with a rare disease better and more meaningful. Andrew received a BA from Cornell University in molecular biology and a PhD from Tufts University School of Medicine in biochemistry. Andrew was a scientist in rare diseases at former Genzyme, now Sanofi, and has worked in BD roles at Sanofi, Novartis, Acceleron, and now Ferrer, where he serves as Head of BD in the United States.
Responsible for managing strategic external global alliances and providing support for Innovation Center pre-deal activities through agreement execution for the Immunology TA at Janssen. Prior to joining Janssen R&D, worked as alliance, project, and portfolio manager in the Gastrointestinal (GI) Drug Discovery Unit, primarily launching and managing external academic and industry alliances within the Immunology portfolio at Takeda Pharmaceuticals. Adna was a scientist and preclinical research manager supporting IND enabling studies in inflammatory diseases before transitioning into business development and product planning at Aldeyra Therapeutics. She got her start in the pharmaceutical industry working as an analytical research associate at Roche LLC in Palo Alto, California.
Eirini is the Evaluations Lead at the Bristol Myers Squibb External Innovation Group (Oncology), responsible for the evaluation and the development of the clinical strategy of external opportunities (early & late stage) in order to maximize the potential of each asset and ensure registrational and commercial success. In addition, she directs the activities of a multi-functional team that manages a broad portfolio of BMS clinical collaborations of Ph1-3 combination trials. Prior to her time at BMS, Eirini held positions of increasing responsibility at Roche External Development and Oncology Clinical Development teams. She holds a PhD in tumor immunology from the University of Edinburgh, UK and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York.
Mark has over 20 years of experience in the pharmaceutical industry and is currently a member of Boehringer Ingelheim’s Venture Fund focused on digital health investments. Prior to joining the Fund, Mark was the Global Head of Contracts and Alliance Management, a team within Business Development and licensing that was responsible for leading transactions and the alliance management of collaborations with academic and biotechnology partners. Mark’s career has afforded diverse roles in drug discovery, operations, CRO management, financial management, and business development.
Rachel Bright is Head of Alliance Management, Virology, at Gilead Sciences, where she leads a team responsible for Gilead’s Virology Strategic Alliances. She has broad scientific and business leadership experience in drug discovery and development, and over 20 years of experience in alliance management, business development, program management and research. Prior to this role Rachel held roles in Alliance Management and Business Development at GRAIL, Corporate Development and Program Management at Geron Inc., and Research at Abbott Vascular. Rachel holds a BSc from Haverford College, PA, and a PhD and Postdoc from Stanford University School of Medicine in Molecular Pharmacology, and received the Certified Licensing Professional accreditation.
Steve Pessagno is an employee of GSK, where he has worked in a variety of commercial, operations, and business development roles in his 25 years at the company. Currently an Alliance Director in GSK’s Worldwide Business Development group, Steve manages a portfolio of strategic alliances (primarily in Oncology), oversees the team’s priority projects for Alliance Management operations, and has held leadership roles on several transformative acquisition and divestment deals (examples include GSK’s acquisitions of Reliant Pharmaceuticals, Stiefel Laboratories, and Tesaro; ViiV Healthcare’s acquisition of the HIV business from Bristol Myers Squibb; and the divestment of GSK’s portfolio of marketed Oncology products to Novartis in 2015). Steve holds degrees from the University of Pennsylvania (BA, Communications) and University of Michigan (MBA), and serves on the Board of Directors (Treasurer, Ex-Officio) of the Coalition Against Childhood Cancer (CAC2.org).
Christian Thomsen, Global Head of CNS BD&L at Boehringer-Ingelheim is responsible for bringing in new opportunities and establishing collaborations supporting and expanding the BI pipeline within neuropsychiatry. Christian earned his PhD in neuropharmacology and has >25 years experience in neuroscience drug discovery from Novo Nordisk and Lundbeck before joining Boehringer-Ingelheim in Jan. 2019 LinkedIn: https://www.linkedin.com/in/christian-thomsen-21a5008/
Deborah Garrard is committed to advancing therapies to improve the lives of cancer patients by leveraging the expertise and breaking down barriers across organizations. She has over 20 years of experience in the biopharma industry working in Alliance Management, Product Leadership, and Clinical Supply Operations. She has a BS in Molecular and Cellular Biology and an Executive MBA, both from the University of Washington.
Jukka Muhonen has over twenty (20) years of experience in deal-making in the Pharma and Biotech industries. During his tenure at Orion Corporation (Espoo, Finland) he has led organizations ranging from Legal Affairs and IPR to Alliance Management and Global Business Development. Through his varied global practice he has developed deep knowledge in creating value via different deal structures and in the management of strategic alliances. He has been responsible for numerous successful licensing and partnering deals, including a number of high-interest licensing deals with Big Pharma companies as counter-parts. His core expertise lies in transactions and M&A, commercial contracts, complex commercial negotiations and in building, managing and restructuring contractual relationships. Since 2012 he is also a CEDR accredited mediator.
Monique joined Moderna in 2019 and is currently Senior Director of Program & Alliance Management overseeing strategic alliances with corporate and academic collaborators in cardiovascular and rare diseases. Prior to Moderna, Monique spent 19 years at Boston Children’s Hospital in the Technology Innovation and Development Office (TIDO) supporting the translation of research and clinical innovations into new products to benefit children and the greater public. At BCH, she developed expertise in intellectual property evaluation and management, contract negotiation, business development and alliance management. Working with researchers and clinicians, she launched the BCH Technology Development Fund, an academic catalyst fund dedicated to de-risking high-impact academic technologies to create a pipeline of investable technologies. To date, The Technology Development Fund has led to the launch of several startups including Affinivax, Rebion and Miach Orthopaedics. Monique holds a PhD in Biochemistry from the Tufts Graduate School of Biomedical Sciences and trained as post-doctoral fellow in cancer biology at Harvard University /BIDMC.
Managing Director
Head of External Innovation Hub China
Head of New Business Development Janssen Asia Pacific
Director Corporate Development and M&A
Program:
An opportunity to interact, discuss and listen to the experts from the industry and enhance your knowledge and skills necessary to help you achieve your goals.
The agenda is structured for the needs of Pharma & Biotech Senior Executives. The HK Summit 2023 aims to help companies to expand their network by meeting Targeted Audience from all the continents, and put together deals to develop their business.
The Summit also serves to provide insight on new paradigms for external innovations & disseminate knowledge through expert speakers, for the best practices in the field of industry partnerships.
How it will work for you?
Identify suitable partners according to your company’s needs, engage through one-to-one meetings / networking sessions and develop your business.
Investment Opportunities with high returns for investor as well as fundraising opportunities for life science companies to expedite your innovations and reach inflection points.
Exhibitions to promote your brands, products, services, solutions, platforms and to develop your business.
One-to-One Meetings:
Meet the right decision makers and achieve your business goals through pre-arranged one-to-one meetings. All attendees will be provided with access to our meeting platform which allows to search and identify potential partners, review information about their business and manage all meeting requests in one dashboard.
16+ Hours of Networking:
Each day of summit you will have dedicated sessions for meetings and socialising. This allows each attendee to enjoy over 16+ hours of networking opportunity to engage with qualified leads.
Pre-Arranged Meetings:
Three weeks in advance, you will receive a secure login to our meeting platform, through which you will be able to send and receive meeting requests to and from partners of your choice so that you can enjoy well organised and pre-arranged meetings during the networking session.
